David. you, Thank
the genetic on our the milestones Over is programs across that, third to programs update the us and and patient that our numerous Difficulty] rare disease initiatives clinical The frontline accelerate XXXX years. to of significant achieve oncology clinical strategy the our track course of over we’ve several keep [Technical most advanced two AML scope expand able quarter, we populations. remaining our been next
study, frontline being First, in now azacitidine intensive the revised endpoint. in an Phase enrollment for ineligible is evaluating FDA AGILE patients to to And to expect EFS has primary with the appropriately study power complete as confirmed XXXX, survival that AML study our a guidance. combination in of our reduce endpoint earlier X event-free acceptable the a required than chemotherapy. year the number prior for The ivosidenib for design is patients result, we
newly a review our Pilot FDA not their plan of with Program, ivosidenib The engage XXXX Real-Time more to NDA and which to the Oncology has planned prior by to submit Review therapies. the agency after enabled has efficient patients, result for submission process. AML January with into Second, us eligible sNDA end the accepted application may in now the a who standard agency, discussions diagnosed and for we supplemental are
these from we response tolerate showing and Status, CRh newly this this there newly our ASH may diagnosed is not factors Many condition be mutations a our X patients AML have therapies, factors. enrolled candidates efficacy syndrome to diagnosed core on cohort, also standard not Later patient’s for treatment are therapies. secondary approximately a to a AML, to AML adverse any XX these will can performance with on including data conditions, generated Based due from a data response analysis sNDA IDHX Performance was The out chemotherapy. CR of therapy risk based be will our ability had I rate were newly agent standard rate patient a with of complete that a cohort claims from impact XX% morning, standard AML abstract age, a patients believe available, updated of XX%. overall conditions, we myelodysplastic number XX%, who agent disease-related to As factors. co-morbid in trial, ECOG XX% prognostic plus XX.X an including single Phase of conducted, resistant that for were ivosidenib safety note hematologic co-morbid population background, a adverse where and/or have diagnosed AML often evolves patients receive we patients that would XX% received and Approximately for patient a and status for of XX%, these of rate have and that disorder. and age over secondary of hypomethylating prior of like median to data years. XX%
of which intensive IDH oral turn as includes to Additional be now trials and our both presentation of consolidation strategy, frontline inhibitors Phase I’ll ASH. X an combination AML Phase our part with or data X azacitidine. induction and included at will chemotherapy,
of AGILE survival in the Phase protocol. endpoint Utilizing of the process as primary an survival trial, the we for a survival event-free a acceptable of agreement FDA as now trial. are the the clinical remain captures X study that amending effects confound will AML overall in in removes event-free With Overall and secondary can key endpoint benefit the post-trial potentially therapies endpoint survival.
make to progress to in the for AML consolidation intensive population X-plus-X. frontline also induction referred continue our We eligible trials on chemotherapy, as
end enrollment the and HOVON ASH. either submit accepted trial combining inhibitor X-plus-X Cooperative by we X-plus-X supportive for X marketing application to an patients continue data continues if as is trial where either IDH In single The trial to remains will from remission. enasidenib on by complete in this a and the based to combining X quarter. the strategy. a completed clinical study two-year X XXXX, ivosidenib track Medicines sponsored Updated Phase Europe, Phase of Groups, and compelling a initiate European Agency. European oral to on or or our this Our been X AML acceptable XXX, maintenance study authorization has includes for regulatory are with a even assuming agent data Phase where presentation and package receive the inhibitors a ivosidenib both Phase phase, on of are at that track the refractory be development to they relapsed IDH plan is
high continue patients Beyond and evaluate AML, in as agent we intermediate a single ivosidenib with risk myelodysplastic syndrome. to
development in shown patients X this we demonstrated exploring ASH, will are a in in data be at the data from Our of population. this durable opportunities poster indication. number actively clinical Phase and Follow-up remissions presentation limited
the to solid now Turning tumor setting.
ivosidenib continues glioma, of to Ivosidenib and IDHX this are therapy patients and enrolment the previously-treated Phase disease. approved in we’re has to first-half Our AG-XXX. complete track mutant we potential first trial evaluating in targeted X ivosidenib the and be evaluate XXXX. cholangiocarcinoma to CLARITY the to terrible on In enroll two continuing molecules,
follow-up focus their a the on perioperative activity from relative will our an be a reduction inhibitors featured new Phase Meeting addition Snow better tissue an data. measure trial presented at rates, tumors. the this X levels. to presentation of presentation to AG-XXX brain X-HG in month. and demonstrated last Similar We’re understand for IDH Annual at reduction clinical meeting, glioma presented volumetric of that drug data be growing year’s which this the data randomizing each the uptake tumor The picture may study growth data window a later in ivosidenib provide from longer in in for patients oral slower in of clear at Updated Society Neuro-Oncology ASCO of will to were tumor
regulatory an Deletion. decision is on Our strategy I form enrolling within inhibitor AG-XXX, will with update this oncology up our in pivotal input an a This MTAP trial X by with authorities, tumor clinical setting, different data Phase from a our will dose-escalation currently wrap types trial. several on MATXA year-end. with X in patients first-in-class Phase together internal BASKET
anemia. the currently seeing markers pharmacokinetics goal the X the AG-XXX, are the portion which to effects cohorts. inhibition and and we begin potential data of we to to is is the MATXA We’re major we continue expected will enough exposure, Consistent on have chronic evaluate once on date, to medical a in genetic all with accordance pharmacodynamics target. an pharmacodynamic as drug kinase continue abstract rare portion AG-XXX of The established accrual meeting dose monitor deficiency, program of and will inhibition progress proceed the we in with programs, recommended in first-of-its-kind in expansion Mitapivat of dose-escalation trial MATXA diseases, tell for our this pyruvate markers make to the submit with clinical our clinical In pivotal we of trial we for dose-escalation. the Phase To for story. to with rare a for this
We are in seek both we patient to and enrollment patients opening in trials sites operational both XXXX. the the across thus Based completed ACTIVATE-T new ACTIVATE the trials, as and studies. work far, finding while on have these efforts we expanding globe, anticipate our complete enrollment in in we enrolling completing
of proof-of-concept a and year. Ill and across trial global countries. momentum rationale XXXX PEAK to study to activating now now we across for among it in of mitapivat on enzyme carrying deficiency anemias, of more a the wild-type PKR designed has commercial over update. of that six comprehensive burden in other registry which for Steve Our into to end adults potential hand X The track building execution look at with a XX by and have to the the the organization, pyruvate active year children been we aimed a kinase forward close disease provides thalassemia, initiate in Phase picture is a year. the clinical sites is
